Table 6 Variables associated with the early clinical response of teicoplanin therapy in patients with complicated MRSA infections: univariate and multivariate analyses
Factors | No of patients with early clinical response (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
Patients with factor | Patients without factor | Crude odds ratio (95% CI) | P-value | Adjusted odds ratio (95%CI) | P-value | |
Enhanced high dose loading regimen | 16/23 (69.6%) | 38/53 (71.7%) | 0.90 (0.31–2.63) | 0.851 | ||
Teicoplanin initial Cmin ≥20 μg/mL | 31/39 (79.5%) | 23/37 (62.2%) | 2.36 (0.09–3.95) | 0.096 | 3.95 (1.25–12.53) | 0.020 |
Blood stream infection | 19/22 (86.4%) | 33/54 (64.8%) | 3.44 (0.90–13.13) | 0.060 | 4.55 (1.10–18.77) | 0.036 |
Respiratory infection | 33/50 (66.0%) | 21/26 (80.8%) | 0.46 (0.15–1.44) | 0.178 | ||
Osteomyelitis and arthritis | 6/9 (66.7%) | 48/67 (71.6%) | 0.79 (0.18–3.49) | 0.713 | ||
Central nervous system | 0/1 (0.0%) | 54/75 (72.0%) | – | 0.289 | ||
Mixed infection with Gram-negative organisms | 22/34 (64.7%) | 32/42 (76.2%) | 0.57 (0.21–1.58) | 0.272 | ||
Therapy for definitive fungal infections | 2/2 (100.0%) | 52/74 (70.3%) | – | 1.000 | ||
Sex (male) | 37/52 (71.2%) | 17/24 (70.8%) | 1.02 (0.35–2.95) | 0.977 | ||
Age (> 65 years) | 38/57 (66.7%) | 16/19 (84.2%) | 0.38 (0.10–1.45) | 0.144 | ||
eGFR< 30 mL/min/1.73 m2 | 8/13 (61.5%) | 46/63 (73.0%) | 0.59 (0.17–2.06) | 0.504 | ||
Body mass index < 18.5 | 22/25 (88.0%) | 32/51 (62.7%) | 4.35 (1.15–16.52) | 0.023 | 2.94 (0.69–12.41) | 0.143 |
Body mass index ≥25 | 4/6 (66.7%) | 50/70 (71.4%) | 0.80 (0.14–4.72) | 1.000 | ||
Heart disease | 29/37 (78.4%) | 25/39 (64.1%) | 2.03 (0.73–5.63) | 0.170 | ||
Chronic renal failure | 11/17 (64.7%) | 43/59 (72.9%) | 0.68 (0.22–2.15) | 0.552 | ||
Diabetes mellitus | 13/20 (65.0%) | 41/56 (73.2%) | 0.68 (0.23–2.03) | 0.487 | ||
Collagen disease | 5/10 (50.0%) | 49/66 (74.2%) | 0.35 (0.09–1.35) | 0.142 | ||
Chronic respiratory disease | 4/8 (50.0%) | 50/68 (73.5%) | 0.36 (0.08–1.59) | 0.219 | ||
Inflammatory bowel disease | 7/9 (77.8%) | 47/67 (70.1%) | 1.49 (0.28–7.80) | 1.000 | ||
Intensive care unit stay (> 3 days) | 13/22 (59.1%) | 41/54 (75.9%) | 0.46 (0.16–1.31) | 0.142 | ||
Liver cirrhosis/chronic hepatic dysfunction | 6/12 (50.0%) | 48/64 (75.0%) | 0.33 (0.09–0.28) | 0.094 | 0.28 (0.07–1.19) | 0.084 |
Malignant tumor | 23/33 (69.7%) | 31/43 (72.1%) | 0.89 (0.33–2.41) | 0.819 | ||
Total parenteral nutrition | 10/16 (62.5%) | 44/60 (73.3%) | 0.61 (0.19–1.94) | 0.536 | ||
Serum albumin < 2.5 g/dL (median) | 32/43 (74.4%) | 22/33 (66.7%) | 1.46 (0.54–3.94) | 0.460 | ||
Ventilator use | 11/22 (50.0%) | 43/54 (79.6%) | 0.26 (0.09–0.74) | 0.010 | 0.54 (0.16–1.86) | 0.330 |
Surgery within 28 days | 10/14 (71.4%) | 44/62 (71.0%) | 1.02 (0.28–3.69) | 1.000 | ||
Transplantation | 2/3 (66.7%) | 52/73 (71.2%) | 0.81 (0.07–9.39) | 1.000 | ||
Steroid use | 9/16 (56.3%) | 45/60 (75.0%) | 0.43 (0.14–1.35) | 0.213 | ||
Immunosuppressive therapy | 2/3 (66.7%) | 52/73 (71.2%) | 0.81 (0.07–9.39) | 1.000 | ||
Anticancer therapy | 8/12 (66.7%) | 46/64 (71.9%) | 0.78 (0.21–2.92) | 0.736 | ||
APACHE II score ≥ 15 | 17/28 (60.7%) | 37/48 (77.1%) | 0.46 (0.17 1.27) | 0.129 | ||
Teicoplanin-resistant MRSA (MIC ≥4 μg/mL) | 0 | 54/76 (71.1%) | – | – | ||